SCOTTSDALE, AZ USA (UroToday.com) - Drs. Elizabeth Mueller and Matt Rutman moderated a poster session for “Female Urology/Incontinence”. Notable abstracts were:
M10: The Efficacy of OnobotulinumtoxinA (BOTOX®) in patients with urge urinary incontinence who failed sacral neuromodulation (InterStim®) (Presented by Dina Kirkpatrick, DO, MPH, MBA). The authors retrospectively reviewed 25 patients who received BOTOX® injection after failure of anticholinergics and 25 patients who received BOTOX® injection after failed InterStim® implantation. In the BOTOX®-only group there was a 58% reduction in urinary incontinence episodes compared to 68% in the group receiving BOTOX® after InterStim®. The mean cystometric capacity in the BOTOX®-only group was 215 mL, in comparison to 303 mL in the BOTOX®/InterStim® group. The peak urinary flow in the BOTOX®-only group was 14.5, in comparison to 14.2 in the BOTOX®/InterStim® group. The authors concluded that in this retrospective analysis there was no significant difference in the outcomes between the two patient groups relative to reduction of urinary incontinence episodes.
M13: The effect on time to revision of an obstructing synthetic mid-urethral sling on reoperation for stress urinary incontinence (Presented by Nitya Abraham, MD). The authors assessed the rate of reoperation for stress urinary incontinence in patients who underwent a revision of an obstructing midurethral sling. This retrospective review identified 107 patients. Forty-three percent had transobturator slings previously placed. The median time to sling revision was 22 months. Fifteen of 107 (14%) ultimately underwent repeat surgery for SUI. On multivariate analysis, women were significantly less likely to undergo reoperation for SUI when sling revision was performed more than 24 months after the initial sling was placed.
M19: Holmium Laser excision of genitourinary mesh exposure following anti-incontinence surgery: Minimum 6 month follow up (Presented by Lauren Wood, MD). The authors reviewed 10 patients who underwent transurethral endoscopic excision using holmium laser (TEEH). One of the patients underwent removal of a stich from a Marshall-Marchetti-Krantz procedure. The mean time from anti-incontinence surgery to onset of symptomatic erosion was 28 months. Four patients eroded into the urethra. Five patients eroded into the bladder. At a median follow up of 27 months after TEEH, 89% of patients reported symptom improvement. Seventy-one percent had no recurrence of eroded mesh on follow-up cystoscopy. Three patients had recurrent SUI after mesh excision. There was an 11% retreatment rate.
Moderated by Elizabeth Mueller, MD and Matt Rutman, MD at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Winter Meeting - February 24 - 28, 2015 - JW Marriott Camelback Inn Resort & Spa - Scottsdale, AZ USA
Reported for UroToday by Drew Freilich, MD. Dr. Freilich is a graduate of the University of Massachusetts Medical School and completed his urology residency at New York Medical College/Westchester Medical Center. He is currently a fellow in Female Urology, Neurourology and Reconstructive Urology at Medical University of South Carolina. He has authored more than 40 peer-reviewed articles, monographs, abstracts, and book chapters and abstracts. Dr. Freilich is a member of the American Urological Association and the Society for Urodynamics and Female Urology.